BR112022024161A2 - Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica - Google Patents

Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica

Info

Publication number
BR112022024161A2
BR112022024161A2 BR112022024161A BR112022024161A BR112022024161A2 BR 112022024161 A2 BR112022024161 A2 BR 112022024161A2 BR 112022024161 A BR112022024161 A BR 112022024161A BR 112022024161 A BR112022024161 A BR 112022024161A BR 112022024161 A2 BR112022024161 A2 BR 112022024161A2
Authority
BR
Brazil
Prior art keywords
antibody
multiespecific
nucleic acid
acid sequence
vector
Prior art date
Application number
BR112022024161A
Other languages
English (en)
Inventor
Lichtlen Peter
Urech David
Hess Christian
Gunde Tea
Simonin Alexandre
Warmuth Stefan
Brock Matthias
Chatterjee Bithi
Johansson Maria
Snell Daniel
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20177337.1A external-priority patent/EP3915580A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of BR112022024161A2 publication Critical patent/BR112022024161A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTICORPO MULTIESPECÍFICO, SEQUÊNCIA DE ÁCIDO NUCLEICO, VETOR, CÉLULA HOSPEDEIRA, MÉTODO PARA PRODUZIR O ANTICORPO MULTIESPECÍFICO E COMPOSIÇÃO FARMACÊUTICA. A presente invenção refere-se a um anticorpo multiespecífico compreendendo dois domínios de ligação baseados em anticorpo, que se liga especificamente à mesotelina (MSLN-BD); e pelo menos um domínio de ligação baseado em anticorpo, que se liga especificamente a CD3 (CD3-BD); em que o referido anticorpo multiespecífico não compreende um polipeptídeo da região Fc de imunoglobulina e em que cada um dos referidos MSLN-BD se liga à mesotelina (MSLN) com uma constante de dissociação monovalente (KD) na faixa de 0,5 a 20 nM, quando medida por SPR. A presente invenção refere-se ainda a sequência(s) de ácido nucleico que codifica(m) o referido anticorpo multiespecífico, vetor(es) compreendendo a(s) referida(s) sequência(s) de ácido nucleico, célula(s) hospedeira(s) compreendendo a(s) referida(s) sequência(s) de ácido nucleico ou referido(s) vetor(es), e um método de produção do referido anticorpo multiespecífico. Adicionalmente, a presente invenção refere-se a composições farmacêuticas compreendendo o referido anticorpo multiespecífico e métodos de uso dos mesmos.
BR112022024161A 2020-05-29 2021-05-28 Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica BR112022024161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20177337.1A EP3915580A1 (en) 2020-05-29 2020-05-29 Multispecific antibody
PCT/EP2021/064427 WO2021239987A1 (en) 2020-05-29 2021-05-28 Multispecific antibody

Publications (1)

Publication Number Publication Date
BR112022024161A2 true BR112022024161A2 (pt) 2023-02-07

Family

ID=84492160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024161A BR112022024161A2 (pt) 2020-05-29 2021-05-28 Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica

Country Status (10)

Country Link
US (1) US20230203162A1 (pt)
EP (1) EP4157352A1 (pt)
JP (1) JP2023526976A (pt)
KR (1) KR20230018397A (pt)
CN (1) CN116134052A (pt)
AU (1) AU2021278317A1 (pt)
BR (1) BR112022024161A2 (pt)
CA (1) CA3184899A1 (pt)
IL (1) IL298076A (pt)
MX (1) MX2022014768A (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL271128B1 (en) * 2017-06-05 2024-06-01 Numab Therapeutics AG New anti-3CD antibodies

Also Published As

Publication number Publication date
MX2022014768A (es) 2023-01-11
EP4157352A1 (en) 2023-04-05
JP2023526976A (ja) 2023-06-26
US20230203162A1 (en) 2023-06-29
IL298076A (en) 2023-01-01
AU2021278317A1 (en) 2022-12-22
CA3184899A1 (en) 2021-12-02
CN116134052A (zh) 2023-05-16
KR20230018397A (ko) 2023-02-07

Similar Documents

Publication Publication Date Title
BR112022013545A2 (pt) Anticorpos anti-tigit e método de uso
BR112018001638A8 (pt) construtos de anticorpo biespecífico que se ligam à mesotelina e cd3
BR112018070823A2 (pt) anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
EA202090247A1 (ru) Антитела против cd166 и их применения
EA202190435A1 (ru) Конструкции на основе антител для связывания cldn18.2 и cd3
CO2021005528A2 (es) Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente
BR112018011058A2 (pt) ?anticorpo, composição, método para tratamento de um indivíduo tendo um câncer, kit de partes, e, uso de um anticorpo ou composição?
BR112022024161A2 (pt) Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica
BR0311799A (pt) Anticorpo monoclonal hpam4
BR112022011669A2 (pt) Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica
CL2023001888A1 (es) Anticuerpos multiespecíficos con especificidad para il-4r e il-31.
RU2015119440A (ru) Стабильные и растворимые антитела
CL2022003515A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
Bonner et al. Location of secretory component on the Fc edge of dimeric IgA1 reveals insight into the role of secretory IgA1 in mucosal immunity
BR112022000755A2 (pt) Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento
BR112018072140A2 (pt) anticorpos anti-basigin humanizados e uso dos mesmos
BR112022013403A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos
Desplantes et al. Affinity biosensors using recombinant native membrane proteins displayed on exosomes: application to botulinum neurotoxin B receptor
BR112022020631A2 (pt) Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula
BR112023022975A2 (pt) Polipeptídeos de ligação ao antígeno bma031 melhorados
BR112019004901A2 (pt) anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, seu método de preparação, molécula de ácido nucleico, vetor recombinante, célula hospedeira, kit de diagnóstico e método para fornecer informações
CO2022010294A2 (es) Anticuerpos cd163 o proteinas de union
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t
Brown et al. A bayesian approach for quantifying trace amounts of antibody aggregates by sedimentation velocity analytical ultracentrifugation
BR112022001017A2 (pt) Anticorpo monoclonal anti-vegf humanizado